



Date: August 13, 2024

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai - 400 051
Stock Code: VAISHALI

Sub: The Company Secures Global Product Registrations. Anticipated to Boost Revenue by 100 Million.

Dear Sir/Madam,

Vaishali Pharma is proud to share a significant and hard-earned milestone in our journey, our Product Registrations are now officially secured across key Global regions.

In the semi regulated and ROW pharmaceutical industry, achieving product registrations is a rigorous process, often taking between 2 to 5 years to complete. This accomplishment is not just a reflection of financial investment but also of the countless hours, extensive documentation, and meticulous efforts dedicated by our team.

Within this challenging landscape, we have successfully obtained 19 registrations across Southern Africa, West Africa, the Gulf region, Latin America, and the ASEAN region. This is a remarkable feat, underscoring our strong global presence and commitment to excellence. These Registrations are anticipated to contribute approximately 100 Million INR to our revenue stream.

This achievement is more than just a milestone – it's a powerful indication of our capacity to navigate complex regulatory environments and emerge stronger. We are poised to leverage this momentum, unlocking new opportunities that will propel us toward even greater success.

Vaishali Pharma Ltd.



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : cs@vaishalipharma.com
investor@vaishalipharma.com
CIN - L52310MH2008PLC181632

Thank you for your continued support and belief in us, as we advance in our mission.
Please find enclosed herewith a copy of Press Release giving information about the same and many more.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,
For Vaishali Pharma Limited

Atul Arvind Vasani
Managing Director
DIN: 02107085



PRESS RELEASE

THE COMPANY SECURES GLOBAL PRODUCT REGISTRATIONS. ANTICIPATED TO BOOST REVENUE BY 100 MILLION.

Mumbai, August 13, 2024: Vaishali Pharma Limited (NSE: - VAISHALI), a Mumbai based Company, engaged in supply of pharmaceutical products to corporates, hospitals and retails stores in all SKUs required. Our products have made its grasp on the overseas market and getting excellent feedback worldwide. The Company is showing consistent agility and innovation by meeting the needs of its customers in both Domestic and International markets.

We, Vaishali Pharma Limited, continue to remain steadfast in our transformation journey, building additional pathways of growth and simultaneously focusing on making the organisation more efficient, and believe that the "Quality is an ongoing process of building and sustaining relationship." Our strong commitment of providing quality products is boosted by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure, resultantly, creating mutually beneficial associations for all parties involved.

In business since 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products - Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 250 + formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Vaishali Pharma is proud to share a significant and hard-earned milestone in our journey, our Product Registrations are now officially secured across key Global regions.

Within this challenging landscape, we have successfully obtained 19 registrations across Southern Africa, West Africa, the Gulf region, Latin America, and the ASEAN region. This is a remarkable feat, underscoring our strong global presence and commitment to excellence. These Registrations are anticipated to contribute approximately 100 Million INR to our revenue stream.



“Quality being the primary goal of our association, is the Strength of our Partnership. We have strong foothold in sourcing various products in India. Wherein Vaishali Pharma, is a 30 years old pharmaceutical organization, entirely involved in International Business Marketing of Pharmaceutical Products; along with Nutraceutical Products for Domestic and International Market. Vaishali Pharma holds altogether 250+ Brands in Finished Formulations, Registered in International Market. Our International associations are entirely backed by the Quality Norms we adhere for All Our Products. This will help Company to achieve milestone and reach to new heights.

Vaishali Pharma Limited fastest-growing and most versatile companies in the industry. It has a strong presence in both the domestic and export markets and is currently a supplier to all leading Indian and multinational pharmaceutical companies. The company has been catering to semi-regulated and non-regulated markets across the globe. For more details please visit: www.vaishalipharma.com

For any Investor Relations query, please contact:

Mr. Ratnesh Singh
Chief Financial Officer

Email: investor@vaishalipharma.com

Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.